Targeting the mTOR pathway in Chromophobe Kidney Cancer

Related Experiment Video

Updated: May 23, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Brian Shuch1, Srinivas Vourganti, Julia C Friend

  • 11. Urologic Oncology Branch, National Cancer Institute, 10 Center Drive, CRC, Building 10, Room 1-5940, Bethesda, MD 20892, USA;

Journal of Cancer
|April 7, 2012
PubMed

Insights

Targeted therapy, specifically mTOR inhibitors like temsirolimus, shows promise for advanced chromophobe kidney cancer (CKC), a rare subtype of renal cell carcinoma (RCC). This study details a patient's positive response and reviews existing literature on targeted treatments for CKC.

Area of Science:

  • Oncology
  • Genitourinary Cancers
  • Renal Cell Carcinoma

Background:

  • Chromophobe kidney cancer (CKC) is a rare subtype of renal cell carcinoma (RCC), comprising about 5% of cases.
  • Research on the biology and targeted therapies for CKC lags behind that for clear cell RCC.
  • Limited clinical experience exists for targeted agents in non-clear cell RCC subtypes.

Purpose of the Study:

  • To evaluate the efficacy of targeted therapy in advanced chromophobe RCC.
  • To review the current literature on targeted therapeutic approaches for chromophobe RCC.
  • To discuss the preclinical rationale for using mTOR inhibitors in chromophobe RCC, including its hereditary form, Birt-Hogg-Dube syndrome.

Main Methods:

  • Case report of a patient with advanced chromophobe RCC treated with temsirolimus.
  • Comprehensive literature review of targeted therapy in chromophobe RCC.
  • Preclinical characterization of Birt-Hogg-Dube syndrome to understand mTOR inhibitor rationale.

Main Results:

  • The patient with advanced chromophobe RCC achieved a durable partial response to temsirolimus.
  • Literature review identified emerging case reports on mTOR inhibitors in chromophobe tumors.
  • Preclinical data supports the use of mTOR inhibitors in hereditary chromophobe kidney cancer.

Conclusions:

  • Targeted therapy, particularly mTOR inhibitors, represents a viable treatment option for advanced chromophobe RCC.
  • Further research and clinical trials are warranted to establish the role of targeted agents in chromophobe RCC.
  • Understanding the molecular pathways, including those in Birt-Hogg-Dube syndrome, can guide therapeutic strategies for rare RCC subtypes.
Keywords:
Chromophobe Kidney CancermTOR inhibitors

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...